We evaluated ubiquitin-proteasome activity in carotid plaques of asymptomatic and symptomatic patients and the effect of rosiglitazone, a peroxisome proliferator-activated receptorgamma activator, in symptomatic plaques. BACKGROUND The role of the ubiquitin-proteasome system, the major pathway for non-lysosomal intracellular protein degradation in eucaryotic cells, in the progression of atherosclerotic plaque to instability is unclear.
Patients with substantial carotid artery narrowing are at increased risk for major stroke (1) , but the pathogenic mechanisms linking carotid atherosclerosis and ischemic brain injury still need to be fully clarified. Clinical trials designed to evaluate the beneficial effects of endarterectomy in symptomatic and asymptomatic patients have focused on plaque ulceration as a risk factor for cerebrovascular events (2) .
The conversion of a stable, asymptomatic lesion to an unstable, ruptured plaque involves many processes, such as the inflammation that plays a central role in the cascade of events that eventually results in plaque erosion and fissuring (3) . In fact, studies examining markers of inflammation demonstrate a relation between inflammation and risk of cardiovascular disease (4) . Furthermore, several studies have shown that inflammation is more common in symptomatic plaques, with greater numbers of macrophages and T-cells detected in the cap of symptomatic plaques (5) , and plaque rupture has been shown to be related to increased inflammation within the plaque rather than plaque morphology or degree of vessel stenosis (6) . Thus, the identification of pathways that may regulate inflammation is critical to the formulation of strategies that may stabilize plaques. However, molecular mechanisms that induce inflammation and subsequent plaque instability are still unknown. There is experimental evidence that the ubiquitin-proteasome system, the major pathway for non-lysosomal intracellular protein degradation in eucaryotic cells, may be involved in a number of biological processes, including inflammation, proliferation, and apoptosis, that are responsible for progression of atherosclerotic plaque to an unstable phenotype (7) . The ubiquitin-mediated proteolytic pathway involves the conjugation of multiple moieties of ubiquitin, a 76-aminoacid polypeptide, to cellular proteins in a multienzymatic process, targeting these proteins to degradation (8) . This ligation of ubiquitin by a series of ubiquitin-conjugating enzymes produces polyubiquitin chains, which serve as targeting signals for degradation of the protein by the proteasome. The multicatalytic proteasome consists of a central catalytic core, the 20S proteasome, and two regulatory 19S complexes (9) . Moreover, the ubiquitin-proteasome pathway is required for activation of nuclear factor kappa B (NFkB), a central transcription factor that regulates inflammatory genes, by degradation of its inhibitory kappa B (IkB) proteins (10) . Although it has been demonstrated that ubiquitin immunoreactivity is enhanced in autopsy coronary specimens from infarcted patients (11) , no evidence exists about the potential role of the ubiquitin-proteasome system in the evolution of atherosclerotic plaques toward instability. We hypothesized that the ubiquitin-proteasome overactivity may enhance the inflammatory potential of atherosclerotic plaques favoring instability. This study was designed to identify differences in inflammatory infiltration and ubiquitin-proteasome activity between carotid plaques of asymptomatic and symptomatic patients. Because experimental and pathological studies suggest that activation of peroxisome proliferator-activated receptor (PPAR)-gamma may reduce inflammation (12) and oxidative stress (13) and inhibit ubiquitin-proteasome activity (14) , the study also evaluated the effect of the PPAR-gamma agonist rosiglitazone on ubiquitin-proteasome activity in carotid plaques of symptomatic patients.
METHODS
Patients. We studied 78 surgical inpatients (44 men, 34 women) undergoing carotid endarterectomy for extracranial high-grade internal carotid artery stenosis (Ն70% luminal narrowing). The study group comprised 38 patients with asymptomatic carotid stenosis (asymptomatic group) and 40 patients who presented with symptoms of cerebral ischemic attack (symptomatic group, "symptomatic" according to North American Symptomatic Carotid Endarterectomy Trial [NASCET] classification). Endarterectomy was performed 120 to 140 days after the onset of symptoms in these patients. During the baseline interview, a previous stroke was assessed by asking, "Did you ever suffer from a stroke diagnosed by a physician?" Medical records of patients who answered yes were checked to verify the diagnosis. A history of transient ischemic attack (TIA) also was assessed during the baseline interview. All TIAs were reviewed by a neurologist. A neurologist reviewed information on all possible strokes. A stroke was diagnosed if the clinical symptoms and neuroimaging were positive. Asymptomatic patients underwent a baseline clinical examination as well as medical history and had never developed neurologic symptoms or cerebral lesions assessed by computed tomography. All patients, both symptomatic and asymptomatic, received computed tomography or magnetic resonance imaging. Percentages of carotid diameter reduction, procedural methods, concomitant therapy, and risk factors did not differ between the two groups (Table 1) . By the time of surgery, all patients were taking long-term aspirin therapy (100 mg/day). The symptomatic patients were randomized to receive rosiglitazone (4 mg twice daily, n ϭ 20) or placebo (n ϭ 20) for 4 months according to human studies evaluating the carotid arterial intima-media thickness progression as well as circulating markers of inflammation after PPAR-gamma agonist treatments (12, 15) . After the treatment period, all patients had undergone endarterectomy. Fasting plasma glucose, insulin, and serum lipids, as well as insulin resistance index (16) , were measured at baseline, monthly, and before endarterectomy. Written informed consent was obtained from all patients before each examination. The local ethics review committee approved the study. Atherectomy specimens. After surgery, the specimens were cut perpendicular to the long axis into two halves. The first half was frozen in liquid nitrogen for the following enzyme-linked immunosorbent assay (ELISA) analysis. A portion of the other half-specimen was immediately immersion-fixed in 10% buffered formalin. Sections were serially cut at 5 m, mounted on lysine-coated slides, and stained with hematoxylin and eosin and with the trichrome method. Carotid artery specimens were analyzed by light microscopy. Immunohistochemistry. After the surgical procedure, samples were immediately frozen in isopentane and cooled in liquid nitrogen. Similar regions of the plaque were analyzed (Fig. 1) Marfella et al. June 20, 2006 June 20, :2444 Ubiquitin-Proteasome Activity in Symptomatic Plaque anti-IkB-beta; and anti-matrix metalloproteinase (MMP)-9 (Santa Cruz Biotechnology, Santa Cruz, California). Specific antibodies that selectively recognized the activated form of nuclear factor-kB (p65 and p50 subunits, Santa Cruz) were used. For each immunohistochemical experiment, a negative control was performed with the primary antibody omitted (data not shown). The specimens were analyzed by an expert pathologist (intraobserver variability 6%) blinded to the patient's diagnosis. Quantitative analysis for histology. CD3-positive T-cells were counted individually and expressed as the number of cells per square millimeter of section area as determined by computer-aided planimetry (defined in later text). Furthermore, we determined the area occupied by CD68-positiverich areas. Analysis of experiments was performed with a personal-computer-based 24-bit color image-analysis system. In brief, electronic images were digitized with a Leica color video camera (Leica Microsystem, Milano, Italy). A color threshold mask for immunostaining was defined to detect the red color by sampling, and the same threshold was applied to all specimens. The percentage of the total area with positive color for each section was recorded. Analysis of immunohistochemistry was performed with a personal computer-based quantitative 24-bit color image analysis system (IM500, Leica Microsystem). Biochemical assays. Plaques were lysed and centrifuged for 10 min at 10,000 g at 4°C. After centrifugation, 20 g of each sample were loaded, electrophoresed in polyacrylamide gel, and electroblotted onto a nitrocellulose membrane. Each determination was repeated at least three times. Ubiquitin, IkB-beta, MMP-9, and nitrotyrosine levels were quantified in plaques using a specific ELISA kit (Santa Cruz; R&D Systems, Minneapolis, Minnesota; Imgenex, San Diego, California). Nuclear extracts from plaque specimens were obtained as described by Ohlsson et al. (17) . We used a specific antibody that selectively recognizes the activated form of the NFkB subunit p65. In addition, we analyzed the expression of the activated p50 subunit by specific Trans-AM NF-kB p50 transcription factor assay kit (Active Motif, Rixensart, Belgium). For the quantitative measurement of the proteasome 20S activity, a specific sodium dodecyl sulfate activation kit (Boston Biochem, Cambridge, Massachusetts) was used. Nitrotyrosine was assayed into the plaque tissue with a kits supplied by Hycult Biotech (Uden, the Netherlands).
Macrophages extraction from atherosclerotic plaques.
Macrophages were selectively extracted from plaques as described by de Vries et al. (18) . Biochemical assay on cell homogenates for ubiquitin and proteasome 20S determinations were performed as illustrated earlier.
Measurement of O 2

؊
. Production of O 2 Ϫ was measured as the superoxide dismutase-inhibitable reduction of cytochrome c as previously described (19) . Isolation and culture of blood monocytes. Peripheral blood monocytes from 20 symptomatic and 20 asymptomatic patients were purified and cultured as described by Cipollone et al. (20) . In brief: human monocytes were isolated from buffy coat preparations purchased from the National Blood Transfusion Service or from whole blood taken from laboratory donors. Mononuclear cells were first isolated by Ficoll-Hypaque sedimentation and then further purified by Percoll density fractionation. Monocytes were identified by flow cytometry analysis according to their characteristic forward and side scatter on a Becton Dickinson FACScan flow cytometer. Purity was further checked by expression of CD14 using monoclonal antibodies (Monoclonal Mouse Anti-Human CD14, Clone TÜ K4, Dako). The purity of monocytes ranged between 80% and 88%. Monocytes from symptomatic patients (24 ϫ 10 6 /4 ml of DME) were cultured in the presence or absence of rosiglitazone (7.0 M for 48 h) and in the presence or absence of MG132 (Calbiochem, 10 mmol/l stock solutions in dimethyl sulfoxide), a specific proteasome inhibitor (10 M for 5 h). At the end of the incubation, adherent monocytes were scraped, collected, and lysed; and ubiquitin (Monoclonal anti-Ubiquitin, Clone 6C1, Sigma, ELISA), proteasome 20S, NFk-B (Anti-NfkBp65, Anti-NfkBp50. Santa Cruz), IkB-beta (Anti-IKKb, Sigma), and O 2 Ϫ production were evaluated. Sirius red staining for collagen content. Sections were stained as described by Cipollone et al. (20) . After dehydration, the sections were observed under polarized light after being placed on coverslips. The sections were photographed with identical exposure settings for each section. Statistical analysis. Data are presented as mean Ϯ SD. Continuous variables were compared among the groups of patients with one-way analysis of variance for normally distributed data and the Kruskal-Wallis test for nonnormally distributed data. The Kolmogorov-Smirnov test was used to assess whether continuous variables were normally distributed or not. We compared data using a Kruskal-Wallis test for triglycerides and insulin. When differences were found among the groups, Bonferroni correction was used to make pairwise comparisons. The Bonferroni correction was used in the comparison of ubiquitin, proteasome, p50, p65, IkB-beta, MMP-9, and O 2 Ϫ production values. A p value Յ0.05 was considered statistically significant. All calculations were performed using the computer program SPSS 12 (SPPS Inc., Chicago, Illinois).
RESULTS
Study population. Demographic data for the study population are presented in Table 1 . Percentage of carotid Table 2) . Compared with the placebo group, the rosiglitazone group presented a significantly smaller portion of plaque area occupied by macrophages (p Ͻ 0.01) and T-lymphocytes (p Ͻ 0.01), as well as lower expression of HLA-DR and higher content of VSMC (p Ͻ 0.01) ( Table 3) . The MMP-9 levels were more abundant in symptomatic compared with asymptomatic lesions (p Ͻ 0.001); in symptomatic patients, MMP-9 levels were more abundant in lesions from placebo compared with the rosiglitazone group (p Ͻ 0.001). Lower content of interstitial collagen was found in plaques of all symptomatic compared with asymptomatic patients. Content of interstitial collagen of plaques from rosiglitazone-treated patients was higher compared with that from placebo-treated patients (p Ͻ 0.01) (Fig. 2) . Ubiquitin-proteasome activity. Immunohistochemistry revealed higher staining of ubiquitin and proteasome 20S in inflammatory cells from symptomatic as compared with asymptomatic patients (p Ͻ 0.01), with the highest staining detected in patients randomized to placebo. A similar pattern of response was seen for ubiquitin plaque levels (p Ͻ 0.001) and proteasome 20S plaque activity (p Ͻ 0.001) (Fig. 3) .
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UBIQUITIN AND PROTEASOME 20S IN MACROPHAGES EX-
TRACTED FROM PLAQUES. In order to identify whether the higher ubiquitin-proteasome levels observed in symptomatic plaques were produced by macrophages, we repeated quantitative analyses on macrophages selectively extracted from seven plaques randomly selected from each of the three groups. The small sample size used was not sufficient to reach an adequate statistical power for the comparisons among groups, so we can describe only the tendency of central measures for the three groups. However, we observed that the placebo symptomatic group had the highest of both ubiquitin levels (468.7 Ϯ 89 ng/mg) and proteasome 20S activity (79.8 Ϯ 25 pmol/mg), the asymptomatic group had the lowest (ubiquitin 218 Ϯ 66 ng/mg; proteasome 20S 26.7 Ϯ 8 pmol/mg), and the rosiglitazone symptomatic group had intermediate levels (ubiquitin 322 Ϯ 79 ng/mg; proteasome 20S 46.8 Ϯ 10 pmol/mg). Colocalization of proteasome 20S and ubiquitin with macrophages in symptomatic plaques. Serial sections of symptomatic plaques were incubated with the primary antibodies anti-ubiquitin, anti-proteasome 20S, and anti-CD68. The expression of both ubiquitin and proteasome 20S were associated with CD68ϩ macrophages in plaque sections (Fig. 4) . Thus, these analyses confirmed the concomitant presence of ubiquitin and proteasome 20S in macrophages of symptomatic plaque. NFkB activity. Nuclear factor kappa B activation, as reflected by the selective analysis of activated form of both p50 and p65, was significantly higher in both placebo (p Ͻ 0.01) and rosiglitazone (p Ͻ 0.01) inflammatory cells as compared with macrophages from asymptomatic patients. In plaques from symptomatic patients, both p50 (p Ͻ 0.01) and p65 (p Ͻ 0.001) were significantly higher in placebo-treated than in rosiglitazone-treated patients. Immunohistochemistry and quantitative analyses revealed lower staining and levels for IkB-beta in inflammatory cells from symptomatic as compared with asymptomatic patients (placebo, p Ͻ 0.01; rosiglitazone, p Ͻ 0.001); moreover, both staining and levels of IkB-beta were higher in rosiglitazone than in placebo symptomatic plaques (Fig. 5) . Quantification of oxidative stress. Higher nitrotyrosine levels were found in symptomatic plaques as compared with asymptomatic plaques (symptomatic placebo 3. Marfella et al. June 20, 2006 June 20, :2444 Ubiquitin-Proteasome Activity in Symptomatic Plaque placebo group 6.26 Ϯ 1.4 pmol/l; symptomatic rosiglitazone group 3.57 Ϯ 1.1 pmol/l; asymptomatic group 2.14 Ϯ 0.88 pmol/l, p Ͻ 0.01). In symptomatic patients, nitrotyrosine levels and O 2 Ϫ production were significantly higher in plaques from placebo-treated compared with rosiglitazonetreated patients (nitrotyrosine: 3.5 Ϯ 0.42 nmol/pg vs. In vitro study. Higher levels of ubiquitin, p50, p65, and O 2 Ϫ production, as well as higher proteasome 20S and lower IkB-beta levels, were evidenced in peripheral blood monocytes from 20 symptomatic patients compared with monocytes from asymptomatic patients (p Ͻ 0.01). Levels of ubiquitin, p50, p65, and O 2 Ϫ production, as well as proteasome 20S activity, were significantly lower in monocytes from symptomatic patients incubated with rosiglitazone than in monocytes from symptomatic patients incubated without rosiglitazone (p Ͻ 0.01). The IkB-beta levels were significantly higher in the symptomatic group monocytes incubated with rosiglitazone than in symptomatic group monocytes incubated without rosiglitazone (p Ͻ 0.01) (Fig.  6) . Levels of p50 and p65 levels were significantly lower in monocytes from symptomatic patients incubated with MG132 than in symptomatic patients' monocytes incubated 
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without MG132 (p50: 15.9 Ϯ 1.4 ng/mg vs. 21 Ϯ 1.7 ng/mg, p Ͻ 0.01; p65: 22 Ϯ 2.9 ng/mg vs. 31.5 Ϯ 1.6 ng/mg, p Ͻ 0.01), whereas IkB-beta (33.6 Ϯ 7.9 ng/mg vs. 18 Ϯ 2.2 ng/mg, p Ͻ 0.01) was significantly higher in the symptomatic group monocytes incubated with MG132 than in symptomatic group monocytes incubated without MG132. Although ubiquitin levels were higher in monocytes incubated with MG132, there were no statistically significant differences among the groups (429.9 Ϯ 27.8 ng/mg vs. 414 Ϯ 49.8 ng/mg, p ϭ 0.2).
DISCUSSION
This study shows that ubiquitin-proteasome system overactivity is associated with the inflammatory process in atherosclerotic plaques of symptomatic patients. In particular, the ubiquitin-proteasome activity was greater in symptomatic atherosclerotic lesions as compared with asymptomatic lesions and was associated with higher NFkB and MMP-9 levels along with a lesser interstitial collagen content and a lesser VSMC content. These alterations might increase the risk of future acute ischemic events precipitated by inflammatory-dependent rupture of atherosclerotic plaques. Moreover, we provide evidence that the PPAR-gamma agonist rosiglitazone may prevent plaque progression to an unstable phenotype in symptomatic patients by reducing ubiquitin-proteasome activity. A previous postmortem study (11) has reported enhanced ubiquitin expression in unstable coronary plaques. However, the study did not provide any evidence about the specific pathway transducing environmental stimuli in ubiquitin-proteasome overexpression in subgroups of high-risk plaques such as those found in symptomatic patients. In our study, macrophages, T-lymphocytes, and HDLA-DRϩ inflammatory cells were more abundant in symptomatic plaques and represented the major source of ubiquitin-proteasome activity, suggesting the presence of an active inflammatory reaction in symptomatic plaques. Concomitantly higher expression of ubiquitin and proteasome was found in human plaque macrophages obtained from the carotid lesions of patients with recent TIA or stroke compared with specimens obtained from asymptomatic patients. In agreement with the difference in ubiquitin-proteasome staining pattern, the histologic milieu of the lesions appears different with regard to cellularity, but not in the degree of vessel stenosis, suggesting that symptomatic and asymptomatic lesions are different only with regard to inflammatory burden. Hence, the differences in plaque behavior likely stem from differences in the presence of stimuli (i.e. oxidative stress, as evidenced by high O 2 Ϫ production and nitrotyrosine levels) for selective expression of ubiquitinproteasome, capable of disrupting plaque stability via NFkB induction. Nuclear factor kappa B is normally bound to IkB in the cytosol; this binding prevents its movement into the nucleus (21) . Various cellular stimuli, such as oxidative stress, induce ubiquitination of phosphorylated IkBs and subsequent degradation by the proteasome (22) . Degradation of IkBs results in unmasking of the nuclear localization signal of NFkB dimers, which subsequently translocates to the nucleus, where it induces the transcription of proinflammatory cytokines that play a central role in plaque instability progression (23, 24) . Our findings also suggest that oxidative stress may induce phosphorylation and degradation of IkBs via the ubiquitinproteasome overactivity, thus enhancing NFkB activation. According to the response-to-injury theory, atherosclerosis is initiated as an inflammatory-proliferative response to an injurious stimulus, constituted by cardiovascular risk factors such as hypercholesterolemia, hypertension, smoking, diabetes, and age (23) . This injurious stimulus seems to be aggravation of endogenous oxidative stress, leading to the oxidative modification of lipids, proteins, and deoxyribonucleic acid, and thereby to structural and functional alterations within the vascular wall (25) . Reduction in the bioavailability of nitric oxide (NO) due to increased production of reactive oxygen species is another important pathophysiologic element in atherogenesis (26) . Under normal conditions, NO is constitutively produced by endothelial cells, antagonizing pro-atherosclerotic processes in part by suppressing the transcriptional activity of NFkB, which has been identified as a pivotal mediator in the inflammatory-proliferative process of atherogenesis (27) . Reduction in NO bioavailability as well as alteration of cell signaling pathways due to an increase in oxidative stress, therefore, leads to the activation of NFkB (28) . Previous reports evidenced the involvement of the ubiquitinproteasome system in NFkB activation, particularly under conditions of aggravated oxidative stress. Oxidative stress is the common factor underlying hypercholesterolemia, hypertension, smoking, diabetes, and age and cardiovascular disease, and may explain the presence of inflammation in all these conditions (29) . Although it is well recognized that inflammation is one manifestation of oxidative stress, and the pathways that generate the mediators of inflammation, such as interleukins, are all induced by oxidative stress (30) , the mechanism by which oxidative stress may be involved in inflammatory process of symptomatic plaques is not fully clarified. In this context, our data suggest a novel mechanism by which oxidative stress, increasing ubiquitinproteasome activity, may mediate inflammatory activity in Figure 5 . (A) Levels of activated nuclear factor kappa B (specific Trans-AM p50 and p65 subunit assay kit) and inhibitory kappa B (IkB)-beta asymptomatic, placebo-treated, and rosiglitazone-treated symptomatic plaques; (B) immunohistochemistry for activated p65 (ϫ630) and p50 (ϫ630) and IkB-beta (ϫ800). Similar regions of the plaque are shown. These results are typical of asymptomatic, placebo-treated, and rosiglitazone-treated symptomatic plaques. *p Ͻ 0.05 compared with placebo group. †p Ͻ 0.05 compared with rosiglitazone group. symptomatic atherosclerotic plaques. Of note, it has been shown that oxidative stress can stimulate the ubiquitin system in macrophages by inducing the expression of components of its enzymatic machinery such as ubiquitinbinding proteins (31) . Accordingly, in cultured monocytes from symptomatic patients we evidenced that O 2 Ϫ production as well as ubiquitin-proteasome activity and NFkB levels were significantly higher when compared to asymptomatic patients. Thus, we can speculate that increased ubiquitin-proteasome activity in plaque macrophage as a consequence of oxidative stress overexpression may enhance the synthesis of NFkB in the same cell, possibly representing a crucial step in the pathophysiology of plaque instability. Because of the study design, we cannot exclude whether the ubiquitin-proteasome pathway exerts also a protective compensatory response (32) , or whether it is merely a correlative marker for the presence of inflammatory cells in symptomatic lesions. However, the concomitant presence of Figure 6 . Ubiquitin, proteasome 20S, activated NFkB, IkB-beta, and O 2 Ϫ production in symptomatic and asymptomatic monocytes. Purified symptomatic monocytes were cultured in presence or absence (48 h) of rosiglitazone (7.0 M). *p Ͻ 0.05 compared with symptomatic monocytes. †p Ͻ 0.05 compared with rosiglitazone-treated symptomatic monocytes. Abbreviations as in Figure 5 .
ubiquitin and proteasome 20S in macrophages of symptomatic patients, as well as the reduction of NFkB levels in monocytes from symptomatic patients treated with proteasome inhibitor suggests that the ubiquitin-proteasome pathway may have a pro-inflammatory effect in symptomatic lesions. Moreover, higher expression of ubiquitinproteasome and MMP-9 in symptomatic plaques, one of the most important enzymes in the process of atherosclerotic plaque rupture (33) , along with a lesser interstitial collagen content suggests an involvement of the ubiquitin proteasome system in instability of symptomatic lesion by increasing plaque erosion.
The present findings also show an inhibitory effect of rosiglitazone on ubiquitin-proteasome activity in symptomatic lesions. Indeed, symptomatic patients treated with rosiglitazone had the lowest level of ubiquitin and proteasome 20S activity, plaque inflammatory cells, cytokines, oxidative stress, and MMP-9 associated with the highest content of plaque interstitial collagen and VSMC content. Thus, patients assigned to rosiglitazone had less plaque progression to rupture compared with patients assigned to placebo. In particular, the reduced ubiquitinproteasome activity seen in symptomatic plaques of the rosiglitazone group suggests decreased IkBs degradation and hence NFkB activation. All this may have clinical implications, because in a large series of carotid endarterectomy specimens, it has been shown that plaque inflammation is one of the major determinants of ischemic events in patients affected by carotid atherosclerotic disease (1) . Sufficient data in humans suggest that PPAR-gamma agonists reduce common carotid arterial intima-media thickness progression as well as circulating markers of inflammation as early as three months after the administration in both nondiabetic and diabetic patients (12, 15) . Moreover, there are accumulating data to suggest that PPAR-gamma agonists exert antiinflammatory and antioxidant effects, including decreases of cytokines and MMPs in monocytes, macrophages, T-lymphocytes, and VSMC (34, 35) . Although PPARgamma agonists may inhibit proteasome activity in human cancer (36) , until now there was no evidence that this effect was reproducible in human atherosclerotic plaques. The hypothesis that plaque ubiquitinproteasome activity is reduced by PPAR-gamma agonists is also supported by our in vitro experiment that evidenced a reduction of ubiquitin-proteasome activity, NFkB levels, and O 2 Ϫ production associated with a significant increment of IkB-beta in monocytes from symptomatic patients treated with rosiglitazone. The mechanism of repression of the proteasome by rosiglitazone remains a mystery and requires further studies. On the other hand, the reduction in O 2 Ϫ production by monocytes after rosiglitazone treatment may allow a lower polyubiquitination, as evidenced by reduction of ubiquitin levels. We therefore speculated that proteasome reduction by rosiglitazone may be induced by inhibition of oxidative stress and polyubiquitination. Rosiglitazone treatment also produced a significant reduction in insulin resistance, as indicated by reduced insulin resistance index levels. As insulin resistance is associated with increased cardiovascular and cerebrovascular risk (37) , improved insulin sensitivity may be one mechanism by which rosiglitazone retards atherogenesis progression. On the other hand, oxidative stress has been shown to induce insulin resistance through NFkB activation (38) : in this perspective, rosiglitazone, by reducing oxidative stress and ubiquitin-proteasome activity, may enhance both insulin sensitivity and symptomatic plaque stability. We also do not exclude the possibility that rosiglitazone inhibits NFkB activation through additional mechanisms independent of PPAR-gamma. Indeed, a PPARgamma-independent pathway may be operative in neuronal cells via inhibition of inducible nitric oxide synthase (39) . Furthermore, PPAR-gamma agonists inhibit the nuclear translocation and subsequent deoxyribonucleic acid binding of NFkB via an IkBs-dependent pathway by inhibiting the immune response-induced degradation of IkBs (40) . This provides evidence that a component of the anti-inflammatory effect is mediated by the action of PPAR-gamma agonists on the systemic immune system.
